Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What is CD4+CD56+ malignancy and how should it be treated?

P Reimer1, T Rüdiger, D Kraemer

  • 1Medizinische Poliklinik, Universitaet Wuerzburg, Wuerzburg, Germany. p.reimer@medizin.uni-wuerzburg.de

Bone Marrow Transplantation
|September 18, 2003
PubMed
Summary

CD4+CD56+ malignancy, a rare cancer, has a poor prognosis. Allogeneic stem cell transplantation in first remission offers improved survival for eligible patients, but optimal treatment for older individuals remains unclear.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contrasting Rare Earth Element Signatures Between Stromatolitic Carbonates and Lagoon Waters at Shark Bay, Western Australia: Implications for Paleo-Environmental Reconstructions of Microbial Habitats.

Geobiology·2026
Same author

Sweat Gland Carcinoma of the Lower Eyelid.

Deutsches Arzteblatt international·2026
Same author

Alleviating the burden of depression: a simulation study on the impact of mental health services.

Epidemiology and psychiatric sciences·2024
Same author

Really just a little prick? A meta-analysis on adverse events in placebo control groups of seasonal influenza vaccination RCTs.

Vaccine·2022
Same author

Diagnostic yield and cost analysis of electrocardiographic screening in Swiss paediatric athletes.

Journal of science and medicine in sport·2021
Same author

EU-CaRE study: Could exercise-based cardiac telerehabilitation also be cost-effective in elderly?

International journal of cardiology·2021

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • CD4+CD56+ malignancy is a rare neoplasm characterized by an aggressive clinical course and high early relapse rates.
  • Despite initial good responses to chemotherapy, long-term outcomes remain poor for most patients.

Purpose of the Study:

  • To evaluate the impact of different therapeutic strategies on the clinical outcome of CD4+CD56+ malignancy.
  • To identify prognostic factors and recommend optimal treatment approaches.

Main Methods:

  • A review of 91 published cases and six additional patient cases.
  • Analysis of clinical features, immunophenotype, cytogenetics, and treatment outcomes.
  • Treatment strategies were categorized into four groups: less intensive chemotherapy, CHOP/CHOP-like regimens, acute leukemia therapy, and stem cell transplantation.

Related Experiment Videos

Main Results:

  • The overall median survival was 13 months.
  • No significant difference in survival was observed between patients with skin-restricted disease and those with advanced disease.
  • Age over 60 years was identified as a negative prognostic factor.
  • High-dose chemo/radiotherapy followed by allogeneic stem cell transplantation in first complete remission was associated with improved survival.

Conclusions:

  • Allogeneic stem cell transplantation in first complete remission is a recommended approach for eligible CD4+CD56+ malignancy patients.
  • The optimal treatment strategy for older patients with this malignancy is currently unknown.